Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Nicholas P, van der Meulen"'
Autor:
Carlos Vinícius Gomes, Bruno Melo Mendes, Lucas Paixão, Silvano Gnesin, Cristina Müller, Nicholas P. van der Meulen, Klaus Strobel, Telma Cristina Ferreira Fonseca, Thiago Viana Miranda Lima
Publikováno v:
EJNMMI Physics, Vol 11, Iss 1, Pp 1-14 (2024)
Abstract Background Several research groups have explored the potential of scandium radionuclides for theragnostic applications due to their longer half-lives and equal or similar coordination chemistry between their diagnostic and therapeutic counte
Externí odkaz:
https://doaj.org/article/b7c6ac5ef101466382ede07370ae5e6b
Autor:
Anzhelika N. Moiseeva, Chiara Favaretto, Zeynep Talip, Pascal V. Grundler, Nicholas P. van der Meulen
Publikováno v:
Frontiers in Nuclear Medicine, Vol 4 (2024)
The interest in terbium radionuclides, which can be used in nuclear medicine, has increased tremendously over the last decade. Several research studies have shown the potential of four terbium radionuclides 149,152,155,161Tb both for cancer diagnosis
Externí odkaz:
https://doaj.org/article/6300e30432ad4bc99fd359021474e8ec
Autor:
Darja Beyer, Christian Vaccarin, Xavier Deupi, Ana Katrina Mapanao, Susan Cohrs, Fan Sozzi-Guo, Pascal V. Grundler, Nicholas P. van der Meulen, Jinling Wang, Matthias Tanriver, Jeffrey W. Bode, Roger Schibli, Cristina Müller
Publikováno v:
EJNMMI Research, Vol 13, Iss 1, Pp 1-14 (2023)
Abstract Purpose The angiotensin converting enzyme-2 (ACE2)—entry receptor of SARS-CoV-2—and its homologue, the angiotensin-converting enzyme (ACE), play a pivotal role in maintaining cardiovascular homeostasis. Potential changes in ACE2 expressi
Externí odkaz:
https://doaj.org/article/ad4f974295474f0392325fbd07ff6ab8
Autor:
Edoardo Renaldin, Gaia Dellepiane, Saverio Braccini, Alexander Sommerhalder, Hui Zhang, Nicholas P. van der Meulen, Robert Eichler, Zeynep Talip
Publikováno v:
Frontiers in Chemistry, Vol 11 (2023)
Introduction: Targeted Radionuclide Therapy is used for the treatment of tumors in nuclear medicine, while sparing healthy tissues. Its application to cancer treatment is expanding. In particular, Auger-electron emitters potentially exhibit high effi
Externí odkaz:
https://doaj.org/article/35ddeb5cb2dc41f08e0565dfc8cd5aa4
Autor:
Jens Hemmingsson, Johanna Svensson, Nicholas P. van der Meulen, Cristina Müller, Peter Bernhardt
Publikováno v:
EJNMMI Physics, Vol 9, Iss 1, Pp 1-13 (2022)
Abstract Background Based on theoretical and preclinical results, terbium-161 may be a valid alternative to lutetium-177 and yttrium-90 in radionuclide therapies. The large low-energy electron emission from terbium-161 is a favorable feature in the t
Externí odkaz:
https://doaj.org/article/59f46f90e5d64539949c700ad637d893
Autor:
Frédéric Juget, Zeynep Talip, Youcef Nedjadi, M. Teresa Durán, Pascal V. Grundler, Jan Rijn Zeevaart, Nicholas P. van der Meulen, Claude Bailat
Publikováno v:
EJNMMI Physics, Vol 9, Iss 1, Pp 1-18 (2022)
Abstract Background 161Tb draws an increasing interest in nuclear medicine for therapeutic applications. More than 99% of the emitted gamma and X-rays of 161Tb have an energy below 100 keV. Consequently, precise activity measurement of 161Tb becomes
Externí odkaz:
https://doaj.org/article/687b6810802745069ee68742726a9d6f
Autor:
Barbara Happl, Marie Brandt, Theresa Balber, Katarína Benčurová, Zeynep Talip, Alexander Voegele, Petra Heffeter, Wolfgang Kandioller, Nicholas P. Van der Meulen, Markus Mitterhauser, Marcus Hacker, Bernhard K. Keppler, Thomas L. Mindt
Publikováno v:
Pharmaceutics, Vol 15, Iss 11, p 2626 (2023)
The first-in-class ruthenium-based chemotherapeutic agent BOLD-100 (formerly IT-139, NKP-1339, KP1339) is currently the subject of clinical evaluation for the treatment of gastric, pancreatic, colorectal and bile duct cancer. A radiolabeled version o
Externí odkaz:
https://doaj.org/article/0103cd691d3e43eabe126bd088ed876e
Autor:
Francisco Alves, Inês F. Antunes, Emiliano Cazzola, Frederik Cleeren, Bart Cornelissen, Antonia Denkova, Jonathan Engle, Alain Faivre-Chauvet, Nic Gillings, Jeroen J. M. A. Hendrikx, Amir R. Jalilian, Nicholas P. van der Meulen, Renata Mikolajczak, Oliver C. Neels, Maroor R. A. Pillai, Raymond Reilly, Sietske Rubow, Yann Seimbille, Sarah Spreckelmeyer, Wiktor Szymanski, Carlotta Taddei
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 6, Iss 1, Pp 1-16 (2021)
Abstract Background The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Results This commentary of highlights has resul
Externí odkaz:
https://doaj.org/article/1e1d1224cf1a42b3b079fc553d8870f9
Publikováno v:
CHIMIA, Vol 74, Iss 12, Pp 939-945 (2020)
he concept of targeted radionuclide therapy (TRT) is the accurate and efficient delivery of radiation to disseminated cancer lesions while minimizing damage to healthy tissue and organs. Critical aspects for successful development of novel radiopharm
Externí odkaz:
https://doaj.org/article/97be37d64a124883b7720a8526c2d4d5
Autor:
Pascal V. Grundler, Robert Eichler, Zeynep Talip, P. August Schubiger, Roger Schibli, Nicholas P. van der Meulen
Publikováno v:
CHIMIA, Vol 74, Iss 12, Pp 968-975 (2020)
Radionuclide production and development has a long history at the Paul Scherrer Institute (PSI) and dates back to the founding times of its forerunner institutions: the Federal Institute for Reactor Research and the Swiss Institute for Nuclear Resear
Externí odkaz:
https://doaj.org/article/d50a69f001c64bf1bdb7a69870943663